Outbreaks of influenza infections are seasonal and can range from regional outbreaks to nationwide epidemics or even global pandemics. Mortality can range from 4 percent to 60 percent for at-risk patient populations, depending on the strain circulating in the environment. Rapid diagnostics can significantly improve patient care and control outbreaks by treating with antivirals and informing patients of proper precautions to reduce spread.
Over the past decade, there has been a large shift in diagnostic options, moving from cell culture to rapid point-of-care testing. Today, multiple CLIA-waved assays are approved and laboratory managers must decide which methods and assays are appropriate for their healthcare environment.
In this webinar, Dr. Faron will discuss current trends in influenza epidemiology, evaluate current FDA-cleared assays, and present the MCW team's findings on a recent time-of-motion study comparing three rapid influenza assays. Overall, these data should aid healthcare providers to improve and implement rapid influenza testing.